Home › Forums › Melanoma Diagnosis: Stage IV › Everything you want to know about the expanded access of PD1 › Reply To: Everything you want to know about the expanded access of PD1
In his presentation and interview @ ASCO, June 2013 –
Melanoma: Long overall survival in patients receiving Nivolumab “But we have long-term responders who didn’t develop any brain metastases, so that suggests that maybe we are controlling disease in the brain,” Phase II trial of ipi monotherapy in melanoma patients with brain metastases,
Ipi has a similar level of activity in brain and non-CNS lesions. Novel treatments for Melanoma brain Metastases, .”this study revealed that ipi has activity in melanoma brain mets…it is unknown whether the treatment was more effective in larger melanoma brain mets in which the highly permeable blood brain barrier may allow greater ingress of activated cytotoxic T cells.”
Melanoma Brain Metastases: Is it time to reassess the bias? “found median survival of malignant effusion (mets in the pleural cavity) patients was significantly shorter than brain met patients (2 vs 8 months).” Therefore, “exclusion of melanoma brain met patients from clinical research programs is no longer justified and alternate investigational approaches, possibly combining local and systemic therapies, are greatly needed for these individuals.”
So….lots of folks are on your side, NJ!!! Hopefully, archaic, irrational decisions will give way to what the data shows very soon and more patients with metastatic melanoma mets to the brain will have greater treatment options, as the data shows more and more the reality of our situation.
Yours, Celeste – chaotciallypreciselifeloveandmelanoma.blogspot.com